細胞免疫療法の世界市場

細胞免疫療法の世界市場は2030年までに336億米ドルに達する見込み

2024年に109億米ドルと推定される細胞免疫療法の世界市場は、2024～2030年の分析期間においてCAGR 20.6%で成長し、2030年には336億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるCAR T細胞療法は、CAGR 24.2%を記録し、分析期間終了時には118億米ドルに達すると予測されます。樹状細胞療法セグメントの成長率は、分析期間のCAGRで21.0%と推定されます。

米国市場は30億米ドルと推定、中国はCAGR 28.2％で成長すると予測

米国の細胞免疫療法市場は、2024年に30億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに81億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは28.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ16.1%と18.6%と予測されています。欧州では、ドイツがCAGR約17.3%で成長すると予測されています。

世界の細胞免疫療法市場- 主要動向と促進要因のまとめ

細胞免疫療法はがん治療にどのような革命をもたらすか？

細胞免疫療法は、悪性細胞を標的として破壊するために身体の免疫システムを活用することで、がん治療の情勢を一変させています。化学療法や放射線療法といった従来の治療法とは異なり、細胞免疫療法は、T細胞やナチュラルキラー（NK）細胞などの人工免疫細胞を活用することで、より的を絞った、長期にわたる可能性のある反応を提供します。この分野で最も注目すべき進歩はCAR-T細胞療法であり、白血病やリンパ腫のような血液がんの治療において目覚ましい成功を収めています。プレシジョンメディシン（精密医療）への注目の高まりとともに、細胞免疫療法は、自己免疫疾患や感染症など、腫瘍学にとどまらない幅広い疾患の治療へと進化しています。遺伝子工学とバイオテクノロジーの開発により、研究者は副作用を最小限に抑えながら患者の予後を改善する次世代細胞療法を開発できるようになっています。規制当局の承認が拡大し、臨床試験で有望な結果が得られるにつれ、細胞免疫療法の採用は今後数年で大幅に増加すると予想されます。

細胞免疫療法の需要が増加している理由は？

がんの罹患率の増加と従来の治療法の限界が、細胞免疫療法の需要を促進しています。患者やヘルスケアプロバイダーは、より少ない副作用でより高い効果をもたらす代替療法を積極的に求めています。さらに、初期のCAR-T療法の成功は、新しい細胞ベースの治療法開発への投資の波に拍車をかけ、免疫療法の応用範囲を広げています。さらに、CRISPRや合成生物学などの遺伝子編集技術の進歩により、科学者は免疫細胞の機能性や特異性を高めることができるようになってきています。同種細胞療法や「既製」細胞療法の出現も、患者由来の自己細胞療法と比較して拡張性があり費用対効果の高い治療ソリューションを提供することから、市場成長を促進する重要な要因となっています。これらの画期的な進歩は、患者へのアクセシビリティを向上させるだけでなく、細胞免疫療法をより実行可能で広範な治療選択肢にしています。

細胞免疫療法市場をリードしている地域は？

北米が細胞免疫療法市場を独占しており、強力なR&D投資、堅調なバイオテクノロジー部門、早期の薬事承認がその原動力となっています。特に米国はCAR-T療法の商業化をリードしており、すでに血液悪性腫瘍に対して複数の治療法がFDA承認を受けています。主要な製薬企業、研究機関、高度なヘルスケアインフラが存在することが、この地域の市場リーダーシップをさらに強化しています。欧州は、ドイツ、英国、フランスなどの国々が臨床研究と治療法の採用で大きく前進しており、その後塵を拝しています。一方、アジア太平洋地域は、中国、日本、韓国などの国々における政府支援の増加、がん罹患率の上昇、バイオテクノロジー能力の拡大により、急速な成長を遂げています。これらの地域の規制当局は承認経路を合理化し、革新的な細胞ベースの治療への迅速なアクセスを促進しています。

市場成長を促す主な要因とは？

細胞免疫療法市場の成長は、細胞工学の進歩、がん領域以外の適応拡大、バイオ医薬品研究開発への投資増加など、いくつかの要因によってもたらされます。また、細胞免疫療法は個々の遺伝子や免疫学的プロファイルに合わせた患者固有の治療開発を可能にするため、個別化医療へのシフトも重要な役割を果たしています。さらに、製造の拡張性を高め、治療コストを削減するための継続的な取り組みが、こうした治療をより身近なものにしています。自動化、AIを駆使した分析、バイオプロセスの最適化により、細胞治療の生産が合理化され、より高い効率性と幅広い市場導入が保証されつつあります。この分野が新たなテクノロジーとアプリケーションの拡大によって進化を続ける中、細胞免疫療法は精密医療と免疫腫瘍学の未来を形作る上で極めて重要な役割を果たすと期待されています。

セグメント

治療法（CAR T細胞療法、樹状細胞療法、NK細胞療法、TIL療法、その他の治療法）、適応症（B細胞悪性腫瘍、前立腺がん適応症、肝がん適応症、腎細胞がん適応症、その他の適応症）、エンドユーザー（病院エンドユーザー、がん研究所エンドユーザー、その他のエンドユーザー）

調査対象企業の例

• AbbVie Inc.
• Adicet Bio, Inc.
• Aduro Biotech, Inc.
• Agenus Inc.
• Amgen Inc.
• Arcellx, Inc.
• AstraZeneca PLC
• BioNTech SE
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Celyad Oncology SA
• Dendreon Pharmaceuticals LLC
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.（Kite Pharma）
• GlaxoSmithKline plc.
• Immunocore Holdings plc
• Iovance Biotherapeutics, Inc.
• Johnson & Johnson
• Kymab Ltd.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Cellular Immunotherapy Market to Reach US$33.6 Billion by 2030

The global market for Cellular Immunotherapy estimated at US$10.9 Billion in the year 2024, is expected to reach US$33.6 Billion by 2030, growing at a CAGR of 20.6% over the analysis period 2024-2030. CAR T Cell Therapy, one of the segments analyzed in the report, is expected to record a 24.2% CAGR and reach US$11.8 Billion by the end of the analysis period. Growth in the Dendritic Cell Therapy segment is estimated at 21.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 28.2% CAGR

The Cellular Immunotherapy market in the U.S. is estimated at US$3.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$8.1 Billion by the year 2030 trailing a CAGR of 28.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.1% and 18.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 17.3% CAGR.

Global Cellular Immunotherapy Market - Key Trends & Drivers Summarized

How Is Cellular Immunotherapy Revolutionizing Cancer Treatment?

Cellular immunotherapy is transforming the landscape of cancer treatment by harnessing the body's immune system to target and destroy malignant cells. Unlike traditional therapies such as chemotherapy and radiation, cellular immunotherapy leverages engineered immune cells, such as T-cells and natural killer (NK) cells, to provide a more targeted and potentially long-lasting response. Among the most notable advancements in this field are CAR-T cell therapies, which have shown remarkable success in treating blood cancers like leukemia and lymphoma. With the increasing focus on precision medicine, cellular immunotherapy is evolving to treat a wider range of conditions beyond oncology, including autoimmune disorders and infectious diseases. Advances in genetic engineering and biotechnology are enabling researchers to develop next-generation cell therapies that improve patient outcomes while minimizing adverse effects. As regulatory approvals expand and clinical trials yield promising results, the adoption of cellular immunotherapy is expected to rise significantly in the coming years.

Why Is the Demand for Cellular Immunotherapy Increasing?

The increasing incidence of cancer and the limitations of conventional treatments are driving demand for cellular immunotherapy. Patients and healthcare providers are actively seeking alternative therapies that offer higher efficacy with fewer side effects. Moreover, the success of early CAR-T therapies has spurred a wave of investment in the development of new cell-based treatments, broadening the scope of immunotherapy applications. Additionally, growing advancements in gene editing technologies such as CRISPR and synthetic biology are enabling scientists to enhance the functionality and specificity of immune cells. The emergence of allogeneic or “off-the-shelf” cellular therapies is also a key factor driving market growth, as they offer scalable and cost-effective treatment solutions compared to patient-derived autologous therapies. These breakthroughs are not only improving patient accessibility but also making cellular immunotherapy a more viable and widespread treatment option.

Which Regions Are Leading the Cellular Immunotherapy Market?

North America dominates the cellular immunotherapy market, fueled by strong R&D investments, a robust biotechnology sector, and early regulatory approvals. The United States, in particular, has led the commercialization of CAR-T therapies, with several FDA-approved treatments already in use for hematologic malignancies. The presence of leading pharmaceutical companies, research institutions, and advanced healthcare infrastructure further bolsters the region’s market leadership. Europe follows closely behind, with countries such as Germany, the UK, and France making significant strides in clinical research and therapy adoption. Meanwhile, the Asia-Pacific region is experiencing rapid growth due to increased government support, rising cancer prevalence, and expanding biotechnology capabilities in countries like China, Japan, and South Korea. Regulatory agencies in these regions are streamlining approval pathways, facilitating faster access to innovative cell-based treatments.

What Are the Key Factors Driving Market Growth?

The growth in the Cellular Immunotherapy market is driven by several factors, including advancements in cell engineering, expanding indications beyond oncology, and increasing investment in biopharmaceutical R&D. The shift toward personalized medicine is also playing a crucial role, as cellular immunotherapy enables the development of patient-specific treatments tailored to individual genetic and immunological profiles. Moreover, ongoing efforts to enhance manufacturing scalability and reduce treatment costs are making these therapies more accessible. The rise of automation, AI-driven analytics, and bioprocess optimization is streamlining cell therapy production, ensuring higher efficiency and broader market adoption. As the field continues to evolve with novel technologies and expanded applications, cellular immunotherapy is expected to play a pivotal role in shaping the future of precision medicine and immuno-oncology.

SCOPE OF STUDY:

The report analyzes the Cellular Immunotherapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Other Therapies); Indication (B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication, Renal Cell Carcinoma Indication, Other Indications); End-Use (Hospitals End-Use, Cancer Institutes End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• AbbVie Inc.
• Adicet Bio, Inc.
• Aduro Biotech, Inc.
• Agenus Inc.
• Amgen Inc.
• Arcellx, Inc.
• AstraZeneca PLC
• BioNTech SE
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Celyad Oncology SA
• Dendreon Pharmaceuticals LLC
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc. (Kite Pharma)
• GlaxoSmithKline plc.
• Immunocore Holdings plc
• Iovance Biotherapeutics, Inc.
• Johnson & Johnson
• Kymab Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Cellular Immunotherapy - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Surge in CAR-T and TCR Therapies Propels Growth of the Cellular Immunotherapy Market
  • Expansion of Oncology Indications Accelerates Therapy Pipeline Development
  • Advancements in Gene Editing Tools Strengthen Cell Engineering Capabilities
  • Increasing Investment in Personalized and Precision Medicine Spurs Innovation
  • Growing Role of Tumor Microenvironment Research Expands Therapeutic Potential
  • Emergence of Allogeneic Therapies Enhances Scalability and Market Access
  • Improved Manufacturing Technologies Drive Cost Efficiency and Product Consistency
  • Strategic Collaborations and Licensing Deals Boost R&D Productivity
  • Expansion of Academic and Industry Consortia Enhances Translational Research
  • Integration of AI and Bioinformatics in Target Identification Enhances Therapy Design
  • Development of Combination Immunotherapy Protocols Expands Efficacy Profiles
  • Growth in Clinical Trial Activity Across Hematological and Solid Tumors Strengthens Commercial Pipeline
  • Rising Interest in Cell Banks and Off-the-Shelf Therapies Accelerates Adoption
  • Technological Advancements in Cell Expansion and Cryopreservation Support Global Access
  • Adoption of Decentralized Manufacturing Models Broadens Regional Production Capabilities
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Cellular Immunotherapy Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Cellular Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Cellular Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Cellular Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for CAR T Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for CAR T Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for CAR T Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Dendritic Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Dendritic Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Dendritic Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for NK Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for NK Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for NK Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for TIL Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for TIL Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for TIL Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for B-Cell Malignancies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for B-Cell Malignancies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for B-Cell Malignancies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Prostate Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Prostate Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Prostate Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Liver Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Liver Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Liver Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Renal Cell Carcinoma Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Renal Cell Carcinoma Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Renal Cell Carcinoma Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Cancer Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Cancer Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Cancer Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 44: USA Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 71: China Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Cellular Immunotherapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Cellular Immunotherapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Cellular Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• FRANCE
  • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 92: France Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 98: France Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: France 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Germany 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Italy 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 119: UK Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 125: UK Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: UK 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Spain 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Russia 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Cellular Immunotherapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Cellular Immunotherapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Cellular Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Australia 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• INDIA
  • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 176: India Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 182: India Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: India 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: South Korea 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Cellular Immunotherapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Cellular Immunotherapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Cellular Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Latin America 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Argentina 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Brazil 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Mexico 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Cellular Immunotherapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Cellular Immunotherapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Cellular Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Middle East 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Iran 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Israel 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: UAE 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• AFRICA
  • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Africa 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION